Company news

Prescient Therapeutics Limited news in 2018

Prescient Therapeutics Limited's news releases, calls and decks from 2018, newest first.

View company

Interim Durability Analysis of PTX-200 Breast Cancer Study

December 9, 2018

September 2018 Appendix 4C - Quarterly

October 31, 2018

Pipeline Collaboration for Next Generation Formulations

October 16, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

Improved manufacturing route for PTX-100

September 2, 2018

Appendix 4E and 2018 Annual Report

August 31, 2018

PTX-200 AML Study Expanded

August 29, 2018

June 2018 Appendix 4C - Quarterly

July 31, 2018

US Patent Granted for PTX-200 for Ovarian Cancer Treatment

July 25, 2018

March 2018 Appendix 4C - Quarterly

April 23, 2018

Response to Aware Query

April 11, 2018

PTX-200 Phase 1b Breast Cancer Trial Results

April 9, 2018

March 2018 Investor Presentation

March 18, 2018

December 2017 Appendix 4C - Quarterly

January 31, 2018

Clinical Trial Updates

January 28, 2018

Decks in 2018